10 results about "Diffuse large B-cell lymphoma" patented technology

The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Top1i) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.

The invention discloses a method for screening a B-cell lymphoma biomarker, and belongs to the technical field of bioinformatics. The invention aims to provide a more accurate and simple method for screening the B-cell lymphoma biomarker. The invention provides a method for screening a B cell lymphoma biomarker. The relation between the infiltration ratio of all cell subgroups of T / NK and myeloid cells and the lifetime of a patient is screened out by utilizing scRNA-seq data of Burki lymphoma, diffuse large B cell lymphoma, follicular lymphoma and spleen marginal region lymphoma and bulk RNA-seq data of a Burki lymphoma and diffuse large B cell lymphoma database. And a theoretical basis is provided for screening survival analysis of lymphoma diseases.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

The invention discloses a protein targeted degradation chimera and application thereof.The protein targeted degradation chimera is novel in chemical structure, has an excellent degradation effect on BCL6 protein, can be used for preparing BCL6 degradation agent medicine, has the prospect of being developed into medicine for treating diseases treated or relieved by degrading the BCL6 protein, and has a good application prospect. The diseases treated or relieved by degrading the BCL6 protein comprise cancers such as Hodgkin's lymphoma, B cell-derived non-Hodgkin's lymphoma, T cell-derived non-Hodgkin's lymphoma, NK / T cell-derived non-Hodgkin's lymphoma, diffuse large B cell lymphoma and the like.

Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric / gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions.

The invention discloses application of NK4 as a target spot in preparation of a product for diagnosing or preventing and treating B-cell lymphoma, and belongs to the technical field of biological medicine. By inhibiting the expression or function of NK4, a Rap1 signal channel is blocked, so that the proliferation of tumor cells is inhibited, and the apoptosis of the tumor cells is induced. The invention provides that NK4 can induce B cell lymphoma, and block NK4 can treat diffuse large B cell lymphoma (DLBCL) by reducing proliferation of the B cell lymphoma and increasing apoptosis of the B cell lymphoma; and NK4 is also a mark of the DLBCL. NK4 and a downstream Rap1 signal channel thereof can be used as diagnosis, treatment and drug development targets of B cell lymphoma.

Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive cell therapies (e.g., chimeric antigen receptor (CAR) T-cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a tumor microenvironment (TME) type based upon a molecular-functional (MF) expression signature of the subject, and determining whether or not the subject is likely to respond to a chimeric antigen receptor (CAR) T-cell therapy based upon the TME type. In some embodiments, the methods comprise determining the lymphoma microenvironment (LME) type of a lymphoma (e.g., Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subjects prognosis based upon the LME type determination.

The present invention relates to combination therapies employing an anti-CD20 / anti-CD3 bispecific antibody in combination with an anti-CD19 / anti-CD28 bispecific antibody and a CD19-targeted 4-1BB (CD137) agonist and the use of these combination therapies for the treatment of B-cell cancer such as diffuse large B cell lymphoma (DLBCL).

A composition, comprising: multiple different decoy oligonucleotides configured to collectively hybridize to DNA molecules derived from a plurality of target genomic regions, wherein each genomic region in the plurality of target genomic regions is differentially methylated in diffuse large B cell lymphoma patients for whom chemotherapy is effective compared to in diffuse large B cell lymphoma patients for whom chemotherapy is ineffective.

The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Topli) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.